Efficacy and safety of long‑course tacrolimus treatment for idiopathic membranous nephropathy
نویسندگان
چکیده
منابع مشابه
comparison of the efficacy of tacrolimus versus cyclosporine in the treatment of idiopathic membranous nephropathy
conclusions cyclosporine and tacrolimus reduce proteinuria and serum creatinine after 6 months. nonetheless, tacrolimus reduces urea and cyclosporine increases it. however, since the prevalence of the side effects of both drugs is similar, tacrolimus has better results in the treatment of imn patients compared with cyclosporine. background immunosuppressive drugs have received the most attentio...
متن کاملTreatment of idiopathic membranous nephropathy.
Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Ri...
متن کاملTherapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
We evaluated the efficacy and safety of tacrolimus (TAC) combined with corticosteroids in treating patients with idiopathic membranous nephropathy (IMN). One hundred seventy-seven biopsy-proven IMN patients were recruited in this retrospective clinical study. Sixty patients received TAC (target blood concentration of 4-8 ng/mL) and 117 patients received daily cyclophosphamide (CYC, 100 mg) comb...
متن کاملIdiopathic membranous nephropathy: diagnosis and treatment.
Idiopathic membranous nephropathy is still the most common glomerular disease associated with nephrotic syndrome. The greater the proteinuria, the greater the long-term risk for renal failure. In addition, patients who have membranous nephropathy with nephrotic syndrome have significant morbidity and mortality, in particular related to thromboembolic and cardiovascular complications. There is n...
متن کاملTreatment with rituximab in idiopathic membranous nephropathy
BACKGROUND Rituximab represents a valid therapeutic option to induce remission in patients with primary glomerulonephritis. Despite several studies proving its efficacy in improving outcomes in patients with membranous nephropathy (MN), its role in therapeutic protocols is not yet defined. METHODS We studied 38 patients with idiopathic MN treated with rituximab (in 13 patients as first-line t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Experimental and Therapeutic Medicine
سال: 2018
ISSN: 1792-0981,1792-1015
DOI: 10.3892/etm.2018.6211